From Stroke to Infection: The Emerging Role of Fibrinogen-to-Albumin Ratio in Predicting Stroke-Associated Pneumonia

从中风到感染:纤维蛋白原与白蛋白比值在预测中风相关性肺炎中的新兴作用

阅读:1

Abstract

BACKGROUND: Stroke-associated pneumonia (SAP) is a commonly encountered complication in patients with acute ischemic stroke (AIS) and is generally manifested within the first week following stroke onset. AIMS: The objectives of this study were to determine the association of the fibrinogen-to-albumin ratio (FAR) with SAP in AIS and to examine the predictive and prognostic utility of FAR for the development of SAP. METHODS: We performed a prospective cohort study involving 44 men with AIS admitted to the stroke unit within 24 hours of onset and followed up for two weeks. Based on clinical outcomes, individual patients were classified into SAP and non-SAP groups, in addition to another 22 age-matched healthy controls. Clinical characteristics, laboratory data, and outcomes were compared for differences, and receiver operating characteristic (ROC) curves were also constructed to observe the predictive capacity of FAR. RESULTS: FAR uniquely distinguished the SAP group from controls with a 95.5% sensitivity and a 100% specificity at a cutoff of 0.079 (area under the curve (AUC)=0.997; p<0.001). FAR also distinguished AIS-only patients from controls with an 81.8% sensitivity and a 95.5% specificity at a cutoff of 0.072 (AUC=0.946; p<0.001). CONCLUSION: FAR is a simple, robust biomarker and may independently predict the risk of SAP in AIS patients. Its very high discriminative accuracy for distinguishing SAP from both non-SAP stroke and healthy controls supports its rationale in early risk stratification and prediction. Usage of FAR in clinical assessment could facilitate the early detection of such patients, allow scope for therapeutic intervention based on individual risk, and reduce SAP-related morbidity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。